356 related articles for article (PubMed ID: 17854250)
1. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
[TBL] [Abstract][Full Text] [Related]
2. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
Kocsis JH; Thase ME; Trivedi MH; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT; Keller MB
J Clin Psychiatry; 2007 Jul; 68(7):1014-23. PubMed ID: 17685736
[TBL] [Abstract][Full Text] [Related]
3. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
[TBL] [Abstract][Full Text] [Related]
4. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
[TBL] [Abstract][Full Text] [Related]
5. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
[TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
Kornstein SG
Expert Rev Neurother; 2008 May; 8(5):737-42. PubMed ID: 18457530
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Rudolph RL; Feiger AD
J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
[TBL] [Abstract][Full Text] [Related]
9. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
10. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
12. Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
Kornstein SG
CNS Spectr; 2006 Dec; 11(12 Suppl 15):28-34. PubMed ID: 17146416
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
14. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
Simon JS; Aguiar LM; Kunz NR; Lei D
J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
[TBL] [Abstract][Full Text] [Related]
15. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
Trivedi MH; Dunner DL; Kornstein SG; Thase ME; Zajecka JM; Rothschild AJ; Friedman ES; Shelton RC; Keller MB; Kocsis JH; Gelenberg A
J Affect Disord; 2010 Nov; 126(3):420-9. PubMed ID: 20510459
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Thase ME
J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
[TBL] [Abstract][Full Text] [Related]
19. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
20. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
Davidson J; Baldwin D; Stein DJ; Kuper E; Benattia I; Ahmed S; Pedersen R; Musgnung J
Arch Gen Psychiatry; 2006 Oct; 63(10):1158-65. PubMed ID: 17015818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
